From surge to stumble and back again, seven cell and gene legends recount their personal favorite breakthroughs in the field.

We speak to one of advanced therapy’s great minds about analog and digital events, and the future of the field.

To see continued progress, the pharma and tech industries must collaborate.

Determining full versus empty capsids remains a key challenge with adeno-associated viral vectors.

Can AI usher in a new age of medicine or is it all hype? In this blog, we go down the rabbit hole.

Exploring the potential of self-amplifying RNA and circular RNA in the future of drug development.

We asked the field’s greatest minds: “What improvements do we need to see in cell and gene supply chains?”

How will bureaucratic red tape affect pharma’ ability to support women seeking abortions?

As new treatment modalities emerge, drug developers are turning to synthetic chemistry – and partners like Veranova.

Diversity, support networks, and unexpected journeys: what nine years of C&G biz wisdom can teach us